-- AFM13 monotherapy: Reported positive data from the preplanned interim 
      analysis for the registration-directed trial in PTCL 
 
   -- AFM13 combination with NK cells: Announced 100% objective response rate 
      in four response evaluable patients, including 2 complete responses 
 
   -- AFM24 monotherapy: AFM24 (phase 1/2a study) completed cohort 4 and is 
      enrolling and treating patients in cohort 5; expansion cohorts expected 
      to start in the second half of 2021 
 
   -- AFM24 combination with NK cells: IND application cleared by the FDA for 
      the combination of AFM24 with NKGen Biotech's SNK-01 NK autologous cell 
      therapy 
 
   -- AFM24 combination with anti PD-L1 antibody: Established a collaboration 
      with Roche to clinically explore the combination of AFM24 with 
      atezolizumab (Tecentriq(R)) 
 
   -- Made continued progress in advancing and forming partnerships with 
      Genentech and Roivant, which triggered payments to Affimed 
 
   -- Pro forma cash and cash equivalents as of December 31, 2020 were 
      approximately EUR244.5 million (inclusive of Q1 equity offering and loan 
      proceeds) with anticipated cash runway into the second half of 2023 
 
   -- Conference call and webcast scheduled for April 15, 2021 at 8:30 a.m. EDT 
 
 
   Heidelberg, Germany, April 15, 2021 -- Affimed N.V. (Nasdaq: AFMD), a 
clinical-stage immuno-oncology company committed to giving patients back 
their innate ability to fight cancer, today reported financial results 
for the year ended December 31, 2020 and provided an update on clinical 
and corporate progress. 
 
   "2020 was an important year for Affimed. We continued to build on the 
strong foundation of our scientific discoveries and made significant 
progress across all our programs. We broadened our clinical pipeline, 
added new collaborations, built a strong balance sheet, appointed key 
senior management executives and ensured that our programs stayed on 
track through the global pandemic," said Dr. Adi Hoess, CEO of Affimed. 
"We entered 2021 with strong momentum, and the recently announced 
positive outcome of our interim futility analysis for our registration 
directed study of AFM13 as monotherapy in PTCL patients, and initial 
data from the trial investigating AFM13 pre-complexed natural killer 
cells in Hodgkin lymphoma patients provide further validation for our 
three-pronged development strategy. As we look ahead into 2021, we 
anticipate numerous additional updates as we advance our programs." 
 
   Clinical Stage Program Updates 
 
   Three-pronged Development Strategy 
 
   Based on preclinical and clinical data, Affimed is pursuing development 
of its innate cell engagers (ICE(R)) as monotherapy, and in combination 
with adoptive NK cell transfer and PD-1/PD-L1 checkpoint inhibitors. 
 
   AFM13 (CD30/CD16A) 
 
 
   -- In March 2021, Affimed reported positive results from the preplanned 
      interim futility analysis for AFM13-202, its phase 2 
      registration-directed study of AFM13 (CD16A/CD30) as monotherapy in 
      patients with relapsed or refractory CD30-positive peripheral T-cell 
      lymphoma (PTCL).   The futility analysis demonstrated that the response 
      rate in Cohort A achieved the predefined threshold for continuation of 
      the study. The response rate in Cohort B was sufficiently comparable to 
      allow merging of both cohorts into a single cohort for all patients with 
      CD30 >1%, per the study protocol. Evidence of anti-tumor response was 
      observed in both cohorts with complete and partial responses. The trial 
      will continue by combining the high- and low-CD30 expressing cohorts into 
      one. 
 
   -- In April 2021, Affimed reported positive initial clinical data from the 
      investigator sponsored trial (IST) at The University of Texas MD Anderson 
      Cancer Center evaluating increasing doses of cord-blood derived NK cells 
      pre-complexed with AFM13 (CD16A/CD30) followed by three weekly infusions 
      of AFM13 monotherapy in patients with recurrent or refractory CD30 
      positive lymphomas. As of March 31, 2021, all four response evaluable 
      patients, including three patients in cohort 1 (1x106 AFM13-cbNK/kg) and 
      one patient in cohort 2 (1x107 AFM13-cbNK/kg), have achieved an objective 
      response, including two complete responses, according to investigator 
      assessments by Lymphoma Response to Immunomodulatory Therapy Criteria 
      (LYRIC). All four patients had relapsed / refractory Hodgkin lymphoma and 
      were heavily pretreated, with between four and 14 previous lines of 
      therapy which in all cases included brentuximab vedotin (Adcetris(R)) and 
      anti-PD1 antibodies. 
 
 
   AFM24 (EGFR/CD16A) 
 
 
   -- AFM24-101, the phase 1/2a clinical trial of AFM24, the EGFR/CD16A 
      targeted ICE(R) for patients with EGFR-expressing solid tumors, completed 
      dose cohort 4 (160 mg) and patients are currently being enrolled and 
      treated in dose cohort 5 (320 mg). Affimed expects to provide an update 
      on the dose escalation and initiate the dose expansion cohorts during 
      2021. 
 
   -- An investigational new drug (IND) application was cleared by the U.S. 
      Food and Drug Administration to investigate the combination of AFM24 with 
      NKGen Biotech's (formerly known as NKMax America) autologous NK cell 
      therapy, SNK01, in a first-in-human proof of concept (POC) trial in 
      patients with EGFR-expressing tumors. Affimed expects to initiate the 
      study in the second half of 2021. 
 
   -- Affimed entered into a clinical collaboration with Roche for a phase 1/2a 
      study evaluating AFM24 in combination with the PD-L1 checkpoint inhibitor 
      atezolizumab (Tecentriq(R)) in EGFR-expressing solid tumors. The phase 1 
      portion of the study will establish a dosing regimen and assess safety 
      for the combination; in the subsequent phase 2a portion of the study, the 
      clinical activity of the combination will be evaluated in specific tumor 
      types. Affimed expects to initiate the study in the second half of 2021. 
 
   -- Preclinical data was presented at AACR 2021 showing the potential of 
      AFM24 as monotherapy and in combination with NK cells. As monotherapy, 
      AFM24 induces tumor cell killing independent of KRAS mutations; and, in 
      combination with adoptive NK cells, it leads to AFM24 dose-dependent 
      tumor regression. 
 
 
   Preclinical and Partnered Programs 
 
 
   -- AFM28 progressed further in IND-enabling studies and Affimed expects an 
      IND application will be filed in the first half of 2022. 
 
   -- In November 2020, Affimed entered into a licensing and strategic 
      collaboration agreement with Roivant Sciences and granted Roivant a 
      license to AFM32 with options for additional ICE(R) molecules against 
      targets not included in Affimed's current pipeline. AFM32 will be 
      investigated in solid tumors. 
 
   -- In August 2020, Affimed announced that Genentech's RO7297089, a 
      CD16A/BCMA targeting ICE(R), is actively recruiting patients into a 
      first-in-human phase 1 trial resulting in the achievement of a milestone 
      payment under the terms of the collaboration. 
 
   -- Affimed entered a collaboration with Artiva Biotherapeutics to assess 
      feasibility and activity of pre-manufactured, co-vialed, cryopreserved, 
      off-the-shelf NK cell combination therapeutics. The R&D collaboration is 
      assessing the feasibility and preclinical activity of combinations of 
      Artiva's allogeneic NK cell product AB-101 and Affimed's ICE(R) molecules, 
      building on earlier preclinical studies demonstrating synergistic 
      cytotoxic activity. 
 
 
   Other Corporate Updates 
 
 
   -- In January 2021, Affimed completed a $115 million underwritten public 
      offering to accelerate and expand the development and manufacturing of 
      its clinical and preclinical ICE(R) molecules. 
 
   -- In January 2021, Affimed entered into a financing agreement with Silicon 
      Valley Bank for up to EUR25 million in term loans, with EUR10 million 
      available at closing. 
 
 
   Full Year 2020 Financial Highlights 
 
   As of December 31, 2020, cash, cash equivalents and current financial 
assets totaled EUR146.9 million compared to EUR104.1 million on December 
31, 2019. The pro forma cash position as of December 31, 2020, including 
net proceeds from the January 2021 underwritten public offering and the 
first tranche of the Silicon Valley Bank loan, would be approximately 
EUR244.5 million. 
 
   Based on its current operating plan and assumptions, Affimed anticipates 
that its cash and cash equivalents will support operations into the 
second half of 2023. 
 
   Net cash used in operating activities for the year ended December 31, 
2020 amounted to EUR19.4 million compared to EUR29.1 million for the 
year ended December 31, 2019. The amount received in 2020 includes an 
initial upfront payment and committed funding of EUR33.3 million (US$ 40 
million) from the Roivant collaboration. 
 
   Total revenue for the year ended December 31, 2020 was EUR28.4 million 
compared with EUR21.4 million for the year ended December 31, 2019. 
Revenue for 2020 and 2019 predominantly relate to the Genentech 
collaboration. Collaboration revenue for the year ended December 31, 
2020 amounted to EUR27.8 million, with EUR26.2 million from the 
Genentech collaboration and EUR1.4 million from the Roivant 
collaboration. Collaboration revenue of EUR19.7 million for the year 
ended December 31, 2019 was from the Genentech collaboration. 
 
   Research and development expenses for 2020 increased 14.2% from EUR43.8 
million in the year ended December 31, 2019 to EUR50.0 million in the 
year ended December 31, 2020, due to higher expenses for AFM24 and our 
other projects and infrastructure investments. 
 
   General and administrative expenses increased 33.6% from EUR10.3 million 
in the year ended December 31, 2019 to EUR13.7 million in the year ended

(MORE TO FOLLOW) Dow Jones Newswires

April 15, 2021 06:30 ET (10:30 GMT)